Rafael Holdings(RFL) Stock Price Today

1.605
-0.065-3.89%

Trading Apr 24 10:39 ET

51.43MMarket Cap-0.76P/E (TTM)

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Teddy123

Mar 26 18:58

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

$Rafael Holdings (RFL.US)$
Major Pharma Merger: Rafael Holdings Gains Phase 3 Rare Disease Asset in Strategic Deal

Jaguar8

Mar 26 18:50

NEWS

$Cyclo Therapeutics(Delisted) (CYTH.US)$ $Rafael Holdings (RFL.US)$
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Wednesday, 26th March at 6:50 am
NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stoc...

Teddy123

Mar 14 13:20

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

$Rafael Holdings (RFL.US)$ $Cyclo Therapeutics(Delisted) (CYTH.US)$
Rafael Holdings Swings to $4.6M Loss as Cyclo Therapeutics Merger Approaches

Meltyy

Oct 11, 2024 14:22

🚨 M&A Update! 🚨

Keep an eye on these recently announced & closed M&As: 👀
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics(Delisted) (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔

Trytosaveabit

Aug 22, 2024 18:53

Update

$Cyclo Therapeutics(Delisted) (CYTH.US)$ $Rafael Holdings (RFL.US)$ Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Cyclo Therapeutics' TransportNPC(TM) Phase 3 clinical trial for Trappsol(R) Cyclo(TM) for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, I...

Market Insights

🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks Show More